Latest news:  New Oncotarget publication: EntreChem's mithralog EC-8042 targets sarcoma cancer…  [ read more ]

News & Press Releases [ subscribe for updates ]

Media (spanish)

New Oncotarget publication: EntreChem's mithralog EC-8042 targets sarcoma cancer stem cells by inhibiting SP1 transcription factor

May 2nd, 2016 - Oviedo (Spain)

The results of a collaborative research from EntreChem SL and the Hospital Universitario Central de Asturias, HUCA (Oviedo, Spain), focused on a new strategy for treating sarcomas, especially targeting the tumor initiating cells…


EntreChem's mithralog EC-8042 promising activity for Ewing sarcoma,
published in Clinical Cancer Research


April 4th, 2016 - Oviedo (Spain)

The research, directed by Patrick Grohar, Ph.D. M.D. screened a panel of mithralogs to establish their ability to inhibit EWS-FLI1 in Ewing sarcoma cell line. Both mithramycin and EC-8042 suppress the activity of EWS-FLI1…


EntreChem's orally active EC-70124 reverts tumorigenic
and stem cell properties in prostate cancer


March 10th, 2016 - Oviedo (Spain)

The research, directed by Dr. Carlo Catapano (IOR), focuses on the frequently activated STAT3 and NF-kB transcription factors  and their blocking by the multi-kinase inhibitor EC-70124…


New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer

December 21th, 2015 - Oviedo (Spain)

Activated kinases were identified by using phosphokinase arrays with human colorectal tumor samples, including the Epidermal Growth Factor Receptor (EGFR), components of the PI3K/mTOR pathway (AKT and S6), and SRC, among others…


EntreChem publishes two studies in Oncotarget regarding activity of EC-70124 and EC-8042 in triple negative breast cancer

October 20th, 2015 - Oviedo (Spain)

The results of a collaborative research focused on searching new strategies for Triple Negative Breast Cancer, which accounts for approximately 15%-25% of all breast cancer cases, have published in two separate research papers…


EntreChem participates in the ERA-IB project «NeBrasCa - Next Generation Immunosuppressants: Brasilicardin synthesized by Nocardia spp»

May 7th, 2015 - Oviedo (Spain)

EntreChem and three Universities from three European countries to cooperate in the project. The European Commission has awarded €1 million to the ERA-IB project…


EntreChem participates in the EU project «BIOCASCADES - Sustainable and Scalable Biocatalytic Cascade Reactions Training Network»

March 1st, 2015 - Oviedo (Spain)

Seven universities and five industrial partners from five European countries to cooperate in the project…


EntreChem presents in ESMO 2014 congress:
Activity of the multi-targeted kinase inhibitor EC-70124 in Colorectal Cancer

September 26th, 2014 - Oviedo (Spain)

The results of focused on searching new strategies for Colorectal Cancer, globally the third most common type of cancer making up about 10% of all worldwide cases, has been presented in a poster at the European Society For Medical Oncology…


EntreChem presents in 2014 ASCO Annual Meeting:
Activity of the multi-targeted kinase inhibitor EC-70124
in Triple Negative Breast Cancer


June 2th, 2014 - Oviedo (Spain)

The results of a collaborative research from EntreChem SL (Oviedo) and the Translational Cancer Research Unit at Albacete University Hospital, CHUA (Albacete, Spain) focused on searching new strategies for Triple Negative Breast Cancer…


EntreChem participates in the synthetic biology project «STREPSYNTH»

January 8th, 2014 - Oviedo (Spain)

EntreChem participates in the FP7 European Collaborative Project STREPSYNTH, whose goal is rewiring Streptomyces bacteria as a cell factory for the cost-effective production of biomolecules. The project has been awarded…


Orally active Entrechem's kinase inhibitor EC-70124 targets prostate tumors overexpressing ESE1/ELF3 and NF-kB

April 30th, 2013 - Oviedo (Spain)

The results of a collaborative research from EntreChem SL (Oviedo) and Institute of Oncology Research (IOR, Bellinzona, Switzerland) focused on searching for a new strategy for Prostate Cancer…


EntreChem closed a financing round totaling 1 million EUR

June 22th, 2012 - Oviedo (Spain)

EntreChem closed a financing round totaling 1 million EUR ($1.25M) with existing shareholders of the company. This all-private funding significantly strengthens the capacities of research and development of the biotech company…


EntreChem's mithralogs show increased potency and higher selectivity for treatment of sarcoma

April 16th, 2012 - Oviedo (Spain)

The results of a collaborative research from EntreChem SL (Oviedo, Spain), the National Cancer Institute (NCI, Bethesda, MD, USA) and Vanderbilt University (Nashville, TN, USA) focused on searching for a new strategy for treating Ewing Sarcoma…


EntreChem's kinase inhibitor shows potential for treatment of head and neck cancer

March 26th, 2012 - Oviedo (Spain)

The results of a public-private collaborative research from EntreChem SL (Oviedo) and CIEMAT (Research Center for Energy, Environment and Technology, in Madrid) focused on searching for a new strategy for Head and Neck Squamous Cell Carcinoma…


EntreChem's developmental drug opens the door to a new strategy for glioblastoma

May 9th, 2011 - Oviedo (Spain)

A multidisciplinar research team from EntreChem SL (Oviedo), Valdecilla Hospital (Santander), University of Cantabria (Santander) and Universiy of Navarra's CIMA (Center for Applied Medical Reseach, Pamplona) has developed a new strategy…


Dr Jesús Cortés joins EntreChem as Director of Molecular Biology

December 30th, 2010 - Oviedo (Spain)

EntreChem announces that Dr Jesús Cortés has joined the company as Director of Molecular Biology…


EntreChem SL closes financing round to develop new molecules for oncology

September 16th, 2010 - Oviedo (Spain)

EntreChem closed a financing round thanks to a mix of private and public funding, in a deal that significantly strengthens the capacities…


AENOR grants EntreChem UNE-166002 certification, an standard for the implementation of a quality R&D management system

February 4th, 2010 - Oviedo (Spain)

AENOR (Spanish Association for Standarization and Certification) has granted EntreChem with the UNE-166002 certification…


EntreChem awarded NEOTEC-2 financing from CDTI

June 25th, 2009 - Oviedo (Spain)

The Centre for the Development of Industrial Technology (CDTI) has awarded EntreChem with a NEOTEC-2 grant…


EntreChem study selected for poster presentation at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics"
held in Geneva from 21-24 October 2008


July 14th, 2008 - Oviedo (Spain)

EntreChem data on the first family of antitumoral molecules being developed by the company have been selected for a poster presentation…


EntreChem and Biomar SA enter a collaborative agreement
to develop new compounds


July 31st, 2007 - Oviedo (Spain)

EntreChem has entered a development agreement with Instituto Biomar SA (León, Spain) to exploit EntreChem proprietary technology…


EntreChem and Laboratoires Servier sign R&D collaborative agreement

October 25th, 2006 - Oviedo (Spain)

EntreChem has entered a collaborative agreement with Laboratoires Servier (Paris, France) to exploit EntreChem proprietary technology…


EntreChem's cofounder interviewed for Nature Biotechnology
Special Report "Biotech in Spain"


September 19th, 2006 - Nature Biothecnology

Dr. Francisco Morís, co-founder and CEO of EntreChem, is interviewed in the September issue of Nature Biotechnology. The issue runs a Special Report about Biotech companies in Spain…


C&EN News cover story mentions EntreChem
glycosylation engineering technology


September 4th, 2006 - Chemical & Engineerig News

Professor of biology José Salas and coworkers at the University of Oviedo, Spain, use a different tack. They insert into microorganisms plasmids that endow them with the ability to synthesize novel sugars, which are then transferred to natural products by glycosyltransferases…


EntreChem enters financing agreement with CDTI

June 22nd, 2006 - Oviedo (Spain)

EntreChem has signed an agreement with The Centre for the Development of Industrial Technology (CDTI) consisting on a reimbursable loan of 400,000 EUR within the NEOTEC program for promotion of newly created companies focused on technology development…


EntreChem secures financing from SRP

April 1st, 2006 - Oviedo (Spain)

EntreChem has signed an agreement with the “Sociedad Regional de Promoción” of the Principality of Asturias for a special loan (a “participative loan”) to finance start-up activities of EntreChem…


EntreChem and Genoma España enter a collaborative agreement

January 28th, 2006 - Oviedo (Spain)

EntreChem has signed an agreement with Genoma España, and it has been incorporated to Genoma’s Technology Portfolio. The agreement supports the creation of the company as well as represents an infusion…

La biotecnología tira del carro investigador

07-10-2013, La Nueva España

La molécula EC-70124 de EntreChem muestra actividad por vía oral en cáncer de próstata

20-05-2013, El Comercio

Los grupos Alimerka y Orejas refuerzan sus posiciones en el laboratorio Entrechem

22-06-2012, La Nueva España

Antitumorales ‘made in’ Asturias

07-07-2011, El País

Tras la química combinatoria, análogos al poder

21-06-2011, Diario Médico

EntreChem necesita 5 millones para curar el tumor cerebral

31-05-2011, Expansión

Una molécula "made in Asturias"

07-04-2011, La Voz de Asturias

Una empresa asturiana desarrolla un fármaco contra el tumor cerebral

07-04-2011, El Comercio

Descubierta una posible diana contra el gliobastoma cerebral resistente

06-04-2011, Diario Médico

Valdecilla descubre cómo eliminar el tumor cerebral más dañino que existe

03-04-2011, El Diario Montañés

Asturbios, EntreChem y Juntas Industriales y Navales, Premios CEEI

29-11-2010, El Comercio

Apoyos asturianos frente al cáncer

22-08-2010, La Nueva España

La biotecnología tiene mucha vida

05-01-2010, La Nueva España

Dos proyectos que superan los límites de la Universidad

15-11-2009, El Comercio

La gran batalla de las ‘spin-offs’

23-02-2009, El Comercio

La investigación asturiana quiere tener crédito

08-12-2008, La Nueva España

Convertir tecnología académica en productos con aplicación en el mundo real

01-10-2008, Fórmula Emprendedores

Excelencia en innovación

26-04-2008, La Nueva España

EntreChem y Bioingetec, nuevas empresas de Biotecnología

15-01-2006, El Comercio

Francisco Morís, químico y director de la primera empresa de biotecnología

12-01-2006, La Voz de Asturias

Francisco Morís dirige la primera empresa en el seno de la Universidad

12-01-2006, La Nueva España

Una forma alternativa de generar riqueza industrial en Asturias

21-12-2005, La Nueva España

EntreChem hará fármacos y productos de valor añadido

02-12-2005, La Nueva España

Genoma España avala el proyecto de patente de la Universidad

02-12-2005, La Voz de Asturias